HOOKIPA Pharma To Report Third Quarter 2020 Financial Results on November 12, 2020
HOOKIPA Pharma Inc. (NASDAQ: HOOK) will release its third-quarter financial results for the period ending September 30, 2020, on November 12, 2020, before the market opens. Notably, the company will not hold a conference call for this earnings release, with plans to conduct such calls only alongside its fourth-quarter earnings.
HOOKIPA develops immunotherapeutics utilizing its proprietary arenavirus platform, aiming for innovative treatments in infectious diseases and oncology.
- The company is advancing its proprietary arenavirus platform, which shows potential for innovative treatments.
- HOOKIPA’s CMV vaccine candidate is in a Phase 2 clinical trial targeting kidney transplant patients.
- Collaboration with Gilead Sciences to research cures for HIV and chronic Hepatitis B could expand the company's portfolio.
- None.
NEW YORK and VIENNA, Austria, Nov. 03, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release financial results for the third quarter ended September 30, 2020 before the market opens on Thursday, November 12, 2020.
The Company will not be conducting a conference call in conjunction with this earnings release. Until otherwise noted, the Company will only conduct an earnings conference call in conjunction with its fourth quarter earnings releases.
About HOOKIPA
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that reprograms the body’s immune system.
HOOKIPA’s proprietary arenavirus-based technologies, non-replicating (VaxWave®) and replicating (TheraT®), induce robust antigen-specific CD8+ T cells and pathogen-neutralizing antibodies. HOOKIPA’s viral vectors target antigen presenting cells in vivo to activate the immune system. Both technologies enable repeat administration to augment and refresh immune responses. As a monotherapy, our replicating arenavirus technology has the potential to induce CD8+ T cell response levels previously not achieved by other immuno-therapy approaches.
HOOKIPA’s non-replicating prophylactic Cytomegalovirus (CMV) vaccine candidate is currently in a Phase 2 clinical trial for patients awaiting kidney transplantation. To expand its infectious disease portfolio, HOOKIPA entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to research arenavirus-based functional cures for HIV and chronic Hepatitis B infections.
In addition, HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens. The lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papilloma Virus 16-positive cancers in a Phase 1/2 clinical trial.
Find out more about HOOKIPA online at www.hookipapharma.com.
| Media | Investors |
| Nina Waibel | Matt Beck |
| Senior Director - Communications | Executive Director - Investor Relations |
| nina.waibel@hookipapharma.com | matthew.beck@hookipapharma.com |
| Media enquiries | |
| Instinctif Partners | |
| hookipa@instinctif.com | |
| +44 (0)20 7457 2020 |
FAQ
When will HOOKIPA release its third-quarter financial results?
Will there be a conference call for the third-quarter earnings release?
What is the main focus of HOOKIPA Pharma's research?
What are the key trials currently underway at HOOKIPA?
